Omnicell (NASDAQ:OMCL) Sets New 12-Month High – What’s Next?

Omnicell, Inc. (NASDAQ:OMCL)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $51.30 and last traded at $51.19, with a volume of 386579 shares changing hands. The stock had previously closed at $50.74.

Analysts Set New Price Targets

OMCL has been the subject of a number of recent research reports. Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. Wells Fargo & Company lifted their price target on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 target price on the stock in a research report on Wednesday, January 7th. Finally, Benchmark lifted their target price on shares of Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $47.83.

Omnicell Price Performance

The company has a market capitalization of $2.30 billion, a PE ratio of 119.05, a PEG ratio of 5.40 and a beta of 0.77. The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. The company’s 50 day moving average price is $41.42 and its 200-day moving average price is $34.48.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 2.52% of the company’s stock.

Institutional Trading of Omnicell

A number of institutional investors have recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in Omnicell by 6.6% in the 3rd quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock worth $196,000 after purchasing an additional 401 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock worth $1,013,000 after buying an additional 424 shares during the last quarter. Martin & Co. Inc. TN lifted its stake in shares of Omnicell by 0.4% in the third quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock worth $3,706,000 after buying an additional 443 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Omnicell by 0.3% during the 3rd quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock worth $4,823,000 after buying an additional 448 shares during the period. Finally, GAMMA Investing LLC grew its stake in Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock valued at $50,000 after buying an additional 458 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.